These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31709578)

  • 1. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia.
    Nalghranyan S; Singh AP; Schinke C
    Am J Hematol; 2020 Feb; 95(2):E34-E35. PubMed ID: 31709578
    [No Abstract]   [Full Text] [Related]  

  • 2. A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia.
    Kupsh A; Arnall J; Voorhees P
    J Oncol Pharm Pract; 2020 Jul; 26(5):1274-1278. PubMed ID: 31865846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma.
    Rahbari KJ; Nosrati JD; Spektor TM; Berenson JR
    Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):e339-e343. PubMed ID: 30033209
    [No Abstract]   [Full Text] [Related]  

  • 4. Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.
    Regidor B; Goldwater MS; Wang J; Bujarski S; Swift R; Eades B; Emamy-Sadr M; Eshagian S; Schwartz G; Spektor TM; Berenson JR
    Ann Hematol; 2021 Aug; 100(8):2061-2070. PubMed ID: 33987683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).
    Gonsalves WI; Buadi FK; Kumar SK
    Eur J Haematol; 2018 Feb; 100(2):215-217. PubMed ID: 29064593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study.
    Tang H; Jia W; Jia S; Dong R; Gao S; Feng J; Dong H; Gu H; Zhang T; Yuan R; Liu X; Cheng L; Zhou S; Gao G
    Am J Hematol; 2024 Jun; 99(6):1177-1179. PubMed ID: 38482543
    [No Abstract]   [Full Text] [Related]  

  • 7. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
    Jelinek T; Mihalyova J; Kascak M; Duras J; Popkova T; Benkova K; Richterova P; Plonkova H; Zuchnicka J; Broskevicova L; Huvarova L; Cerna L; Growkova K; Simicek M; Havel M; Gumulec J; Navratil M; Koristek Z; Paiva B; Hajek R
    Am J Hematol; 2019 Jan; 94(1):E35-E37. PubMed ID: 30370955
    [No Abstract]   [Full Text] [Related]  

  • 8. Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
    Fischer K; Al-Sawaf O; Fink AM; Dixon M; Bahlo J; Warburton S; Kipps TJ; Weinkove R; Robinson S; Seiler T; Opat S; Owen C; López J; Humphrey K; Humerickhouse R; Tausch E; Frenzel L; Eichhorst B; Wendtner CM; Stilgenbauer S; Langerak AW; van Dongen JJM; Böttcher S; Ritgen M; Goede V; Mobasher M; Hallek M
    Blood; 2017 May; 129(19):2702-2705. PubMed ID: 28325865
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasma cell leukaemia with t(11;14) not responsive to venetoclax.
    Abu Zaanona MI; Patel P
    BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33495184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe-BIRD) in a child with relapsed/refractory B-cell acute lymphoblastic leukemia with TP53 mutation.
    Mohan V; Jain S; Naithani R
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31152. PubMed ID: 38953139
    [No Abstract]   [Full Text] [Related]  

  • 11. Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma.
    Nakamura A; Suzuki S; Kanasugi J; Ejiri M; Hanamura I; Ueda R; Seto M; Takami A
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.
    Shahswar R; Beutel G; Klement P; Rehberg A; Gabdoulline R; Koenecke C; Markel D; Eggers H; Eder M; Stadler M; Hambach L; Ehrlich S; Göhring G; Schlegelberger B; Dammann E; Reuter M; Wichmann M; Neziri B; Ganser A; Thol F; Heuser M
    Br J Haematol; 2020 Feb; 188(3):e11-e15. PubMed ID: 31681986
    [No Abstract]   [Full Text] [Related]  

  • 13. Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.
    Tremblay D; Feld J; Dougherty M; Czaplinska T; Sanchez G; Kremyanskaya M; Bar-Natan M; Shih AH; Keyzner A; Mascarenhas J
    Leuk Res; 2020 Nov; 98():106456. PubMed ID: 33002673
    [No Abstract]   [Full Text] [Related]  

  • 14. Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?
    Premkumar V; Comenzo R; Lentzsch S
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):686-688. PubMed ID: 31399374
    [No Abstract]   [Full Text] [Related]  

  • 15. Secondary plasma cell leukaemia treated with single agent venetoclax.
    Glavey SV; Flanagan L; Bleach R; Kelly C; Quinn J; Ní Chonghaile T; Murphy P
    Br J Haematol; 2020 Aug; 190(4):e242-e245. PubMed ID: 32525557
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Freise KJ; Jones AK; Eckert D; Mensing S; Wong SL; Humerickhouse RA; Awni WM; Salem AH
    Clin Pharmacokinet; 2017 May; 56(5):515-523. PubMed ID: 27638334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
    N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.
    Jelinek T; Popkova T; Duras J; Mihalyova J; Kascak M; Benkova K; Plonkova H; Cerna L; Koristek Z; Simicek M; Hajek R
    Hematol Oncol; 2020 Aug; 38(3):412-414. PubMed ID: 32323881
    [No Abstract]   [Full Text] [Related]  

  • 19. Venetoclax in the treatment of chronic lymphocytic leukemia.
    Korycka-Wolowiec A; Wolowiec D; Kubiak-Mlonka A; Robak T
    Expert Opin Drug Metab Toxicol; 2019 May; 15(5):353-366. PubMed ID: 30969139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax plus rituximab for chronic lymphocytic leukaemia.
    Stirrups R
    Lancet Oncol; 2018 May; 19(5):e233. PubMed ID: 29606585
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.